XWELL Inc Surges 158% After $31.3 Million Private Placement Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: Benzinga
XWELL shares surged 158% after the announcement of a private placement expected to generate approximately $31.3 million in gross proceeds, reaching a 20-day high of $0.98 in after-hours trading.
The surge is attributed to XWELL's announcement of a private placement with American Ventures, LLC, involving the issuance of about 31,333 shares of Series H Convertible Preferred Stock. This strategic move is expected to enhance the company's capital structure and financial health, as $5.95 million of the proceeds will be used to repurchase certain notes and redeem Series G preferred stock. Despite this positive development, XWELL's market capitalization remains low at $2.19 million, reflecting ongoing market challenges.
The implications of this financing plan could lead to improved financial stability for XWELL, although the company still faces significant hurdles given its recent market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XWEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XWEL
About XWEL
XWELL, Inc. is a global wellness company. The Company delivers restorative and health-focused services to travelers through its three operating segments: XpresSpa, XpresTest, and Naples Wax Center. XpresSpa operates spa service locations in major airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the Centers for Disease Control and Prevention's (CDC's) bio-surveillance program. The Naples Wax Center segment operates six locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. Its health wellness beauty services include massage, waxing, facials, stretch, light emitting diode (LED) light therapy, meditation, manicures, pedicures, aromatherapy, anti-aging treatments, compression therapy, and massage chairs. Its subsidiaries include Naples Wax FRM LLC, Quantum Stream Inc., XpresSpa Holdings, LLC, XpresTest, Inc., and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
XWELL Divests Business to Reshape Strategic Direction
- Strategic Restructuring: XWELL has signed an agreement with Face Haus to divest its XpresSpa and XpresTest businesses for $13 million, aiming to enhance shareholder value by simplifying its business portfolio and paving the way for a new strategic direction in the national security sector.
- Enhanced Capital Deployment: The divestiture is expected to strengthen XWELL's ability to allocate capital toward future growth initiatives, supporting the company's expansion into new markets while maintaining financial discipline for long-term success.
- Operational Efficiency Improvement: XWELL will continue to streamline operations, reduce operating expenses, and allocate capital to projects aligned with its evolving business strategy, ensuring effective execution in its new business direction.
- Shareholder Approval Required: The transaction is expected to close later in 2026, subject to XWELL shareholder approval and the satisfaction of other closing conditions, demonstrating the company's commitment to transparency and compliance during its strategic transformation.
See More
XWEL Sells XpresSpa and XpresTest for $13M
- Business Sale: XWEL announced a definitive agreement to sell its XpresSpa and XpresTest businesses to Express Wellness Group for $13 million, aiming to maximize shareholder value through this divestiture.
- Strategic Shift: This divestiture will provide XWEL with funds to support its strategic pivot into the national security sector, indicating a significant shift in the company's business focus to adapt to market changes.
- Transaction Timeline: The transaction is expected to close later in 2026, a timeline that may impact the company's short-term financial performance and market confidence.
- Stock Price Reaction: Following the announcement, XWEL's shares fell by 13.72%, reflecting market concerns regarding the company's future strategy and financial health.
See More
Trump Family-Linked Investment Backs XWell's AI Screening Rollout
- Investment Scale: An investment vehicle linked to the Trump family, through Dominari Securities, has agreed to purchase approximately $31 million in convertible shares of XWell (XWEL), aiming to roll out AI-driven infectious disease screening at U.S. airports for the 2026 football World Cup, indicating strong confidence in the health tech sector.
- Partnership Development: XWell has partnered with AI predictive analytics startup PieQ to deploy a 'next generation intelligence layer' designed to manage anticipated surges in U.S.-bound travel during major international events, thereby enhancing its competitive position in the market.
- Market Reaction: Despite XWell (XWEL) trading about 3% lower in pre-market hours on Monday, the stock surged over 200% at the end of February following the announcement of a private placement with American Ventures, reflecting a positive market response to the scale of the funding relative to its sub-$10 million market capitalization at that time.
- Brand Strategy: XWell operates several brands, including XpresSpa, providing wellness services and medical screenings at airports, and with the upcoming World Cup, it is expected to significantly enhance its influence in the airport health services market.
See More
XWELL Reports FY 2025 Financial Results with $29.2M Revenue
- Revenue Performance: XWELL reported a revenue of $29.2 million for FY 2025, indicating a continued presence in the market despite a decline compared to the previous year.
- Cost of Sales: The cost of sales for FY 2025 was approximately $21.7 million, down from $25.0 million in the prior year, suggesting progress in cost management efforts.
- Operating Expenses: Operating expenses for FY 2025 totaled approximately $23.2 million, a decrease from $25.6 million in the previous year, reflecting effective spending management by the company.
- Net Loss: The net loss attributable to XWELL for FY 2025 was approximately $17.0 million, slightly higher than the $16.9 million reported in the prior year, indicating ongoing challenges in achieving profitability.
See More
XWELL Shares Surge 221% Following $31.3 Million Private Placement Announcement
- Significant Financing: XWELL has entered into a securities purchase agreement with American Ventures to raise approximately $31.3 million through the issuance of Series H Convertible Preferred Stock, which is expected to significantly enhance the company's capital structure and liquidity.
- Stock Price Surge: XWELL shares surged 221.43% on Wednesday, closing at $1.22, reflecting strong market optimism regarding the financing, which may attract more investor interest.
- Clear Use of Proceeds: The company plans to utilize the raised funds to repurchase $5.95 million of certain notes and redeem its Series G preferred stock, with a total cash outlay of $9 million, which will help reduce financial costs and optimize its capital structure.
- Transaction Completion Imminent: The private placement is anticipated to close on or around Thursday, further boosting market confidence in XWELL's future growth potential and potentially laying a solid foundation for the company's subsequent development.
See More
XWELL Completes $31.3 Million Private Placement
- Private Placement Details: XWELL signed a securities purchase agreement with American Ventures to sell 31,333 shares of Series H Preferred Stock at $1,000 each, with the transaction expected to close on February 26, 2026, and proceeds earmarked for repurchasing $6 million in notes and redeeming certain preferred shares.
- Stock Performance Recovery: XWEL shares surged above $1 for the first time since October 28, 2025, indicating a recovery after receiving a Nasdaq minimum bid price deficiency notice, as the company aims to maintain its stock price to avoid delisting risks.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', with expectations for the stock to rise to $2, reflecting increased investor confidence in the company's future performance, as the stock has gained nearly 220% year-to-date.
- Clear Use of Funds: The funds from this transaction will be used to repurchase warrants covering 8.8 million common shares for $9 million, while the remaining proceeds will support general business expenses and working capital, demonstrating the company's focus on financial health.
See More
XWELL Divests Business to Reshape Strategic Direction
- Strategic Restructuring: XWELL has signed an agreement with Face Haus to divest its XpresSpa and XpresTest businesses for $13 million, aiming to enhance shareholder value by simplifying its business portfolio and paving the way for a new strategic direction in the national security sector.
- Enhanced Capital Deployment: The divestiture is expected to strengthen XWELL's ability to allocate capital toward future growth initiatives, supporting the company's expansion into new markets while maintaining financial discipline for long-term success.
- Operational Efficiency Improvement: XWELL will continue to streamline operations, reduce operating expenses, and allocate capital to projects aligned with its evolving business strategy, ensuring effective execution in its new business direction.
- Shareholder Approval Required: The transaction is expected to close later in 2026, subject to XWELL shareholder approval and the satisfaction of other closing conditions, demonstrating the company's commitment to transparency and compliance during its strategic transformation.
See More
XWEL Sells XpresSpa and XpresTest for $13M
- Business Sale: XWEL announced a definitive agreement to sell its XpresSpa and XpresTest businesses to Express Wellness Group for $13 million, aiming to maximize shareholder value through this divestiture.
- Strategic Shift: This divestiture will provide XWEL with funds to support its strategic pivot into the national security sector, indicating a significant shift in the company's business focus to adapt to market changes.
- Transaction Timeline: The transaction is expected to close later in 2026, a timeline that may impact the company's short-term financial performance and market confidence.
- Stock Price Reaction: Following the announcement, XWEL's shares fell by 13.72%, reflecting market concerns regarding the company's future strategy and financial health.
See More
Trump Family-Linked Investment Backs XWell's AI Screening Rollout
- Investment Scale: An investment vehicle linked to the Trump family, through Dominari Securities, has agreed to purchase approximately $31 million in convertible shares of XWell (XWEL), aiming to roll out AI-driven infectious disease screening at U.S. airports for the 2026 football World Cup, indicating strong confidence in the health tech sector.
- Partnership Development: XWell has partnered with AI predictive analytics startup PieQ to deploy a 'next generation intelligence layer' designed to manage anticipated surges in U.S.-bound travel during major international events, thereby enhancing its competitive position in the market.
- Market Reaction: Despite XWell (XWEL) trading about 3% lower in pre-market hours on Monday, the stock surged over 200% at the end of February following the announcement of a private placement with American Ventures, reflecting a positive market response to the scale of the funding relative to its sub-$10 million market capitalization at that time.
- Brand Strategy: XWell operates several brands, including XpresSpa, providing wellness services and medical screenings at airports, and with the upcoming World Cup, it is expected to significantly enhance its influence in the airport health services market.
See More
XWELL Reports FY 2025 Financial Results with $29.2M Revenue
- Revenue Performance: XWELL reported a revenue of $29.2 million for FY 2025, indicating a continued presence in the market despite a decline compared to the previous year.
- Cost of Sales: The cost of sales for FY 2025 was approximately $21.7 million, down from $25.0 million in the prior year, suggesting progress in cost management efforts.
- Operating Expenses: Operating expenses for FY 2025 totaled approximately $23.2 million, a decrease from $25.6 million in the previous year, reflecting effective spending management by the company.
- Net Loss: The net loss attributable to XWELL for FY 2025 was approximately $17.0 million, slightly higher than the $16.9 million reported in the prior year, indicating ongoing challenges in achieving profitability.
See More
XWELL Shares Surge 221% Following $31.3 Million Private Placement Announcement
- Significant Financing: XWELL has entered into a securities purchase agreement with American Ventures to raise approximately $31.3 million through the issuance of Series H Convertible Preferred Stock, which is expected to significantly enhance the company's capital structure and liquidity.
- Stock Price Surge: XWELL shares surged 221.43% on Wednesday, closing at $1.22, reflecting strong market optimism regarding the financing, which may attract more investor interest.
- Clear Use of Proceeds: The company plans to utilize the raised funds to repurchase $5.95 million of certain notes and redeem its Series G preferred stock, with a total cash outlay of $9 million, which will help reduce financial costs and optimize its capital structure.
- Transaction Completion Imminent: The private placement is anticipated to close on or around Thursday, further boosting market confidence in XWELL's future growth potential and potentially laying a solid foundation for the company's subsequent development.
See More
XWELL Completes $31.3 Million Private Placement
- Private Placement Details: XWELL signed a securities purchase agreement with American Ventures to sell 31,333 shares of Series H Preferred Stock at $1,000 each, with the transaction expected to close on February 26, 2026, and proceeds earmarked for repurchasing $6 million in notes and redeeming certain preferred shares.
- Stock Performance Recovery: XWEL shares surged above $1 for the first time since October 28, 2025, indicating a recovery after receiving a Nasdaq minimum bid price deficiency notice, as the company aims to maintain its stock price to avoid delisting risks.
- Market Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', with expectations for the stock to rise to $2, reflecting increased investor confidence in the company's future performance, as the stock has gained nearly 220% year-to-date.
- Clear Use of Funds: The funds from this transaction will be used to repurchase warrants covering 8.8 million common shares for $9 million, while the remaining proceeds will support general business expenses and working capital, demonstrating the company's focus on financial health.
See More
